While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
Read the full article on CNBC
Read Full Article →